Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

Lorenzo Canti; Kevin K Ariën; Isabelle Desombere; Stéphanie Humblet-Baron; Pieter Pannus; Leo Heyndrickx; Aurélie Henry; Sophie Servais; Evelyne Willems; Grégory Ehx; Stanislas Goriely; Laurence Seidel; Johan Michiels; Betty Willems; Maria E Goossens; Yves Beguin; Arnaud Marchant; Frédéric Baron

doi:10.1016/j.ccell.2022.02.005

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

Lorenzo Canti
, Kevin K Ariën
, Isabelle Desombere
, Stéphanie Humblet-Baron
, Pieter Pannus
, Leo Heyndrickx
, Aurélie Henry
, Sophie Servais
, Evelyne Willems
, Grégory Ehx
, Stanislas Goriely
, Laurence Seidel
, Johan Michiels
, Betty Willems
, Maria E Goossens
, Yves Beguin
, Arnaud Marchant
, Frédéric Baron

Virology

Research output: Contribution to journal › A1: Peer-reviewed journal articles › peer-review

70 Downloads (Pure)

Original language	English
Journal	Cancer Cell
Volume	40
Issue number	4
Pages (from-to)	335-337
Number of pages	3
ISSN	1535-6108
DOIs	https://doi.org/10.1016/j.ccell.2022.02.005
Publication status	Published - 2022

Keywords

Antibody Formation
BNT162 Vaccine
COVID-19/prevention & control
Humans
SARS-CoV-2
Vaccination

Access to Document

10.1016/j.ccell.2022.02.005Licence: Other

2022ccel0001Final published version, 254 KBLicence: Other

ImmCoV: Are SARS-CoV-2 specific antibodies a correlate for protection?)
Ariën, K. (Promotor) & Janssens, N. (Administrator)
Research Fund - Flanders
22/05/20 → 31/05/23
Project: Research Project

Cite this

Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., Henry, A., Servais, S., Willems, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A., & Baron, F. (2022). Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. Cancer Cell, 40(4), 335-337. https://doi.org/10.1016/j.ccell.2022.02.005

@article{3b04c6acc36b4bc3b3e5361a2b484fd4,

title = "Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients",

keywords = "Antibody Formation, BNT162 Vaccine, COVID-19/prevention \& control, Humans, SARS-CoV-2, Vaccination",

author = "Lorenzo Canti and Ari{\"e}n, \{Kevin K\} and Isabelle Desombere and St{\'e}phanie Humblet-Baron and Pieter Pannus and Leo Heyndrickx and Aur{\'e}lie Henry and Sophie Servais and Evelyne Willems and Gr{\'e}gory Ehx and Stanislas Goriely and Laurence Seidel and Johan Michiels and Betty Willems and Goossens, \{Maria E\} and Yves Beguin and Arnaud Marchant and Fr{\'e}d{\'e}ric Baron",

note = "FTX; (Elsevier User License)",

year = "2022",

doi = "10.1016/j.ccell.2022.02.005",

language = "English",

volume = "40",

pages = "335--337",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "4",

}

Canti, L, Ariën, KK, Desombere, I, Humblet-Baron, S, Pannus, P, Heyndrickx, L, Henry, A, Servais, S, Willems, E, Ehx, G, Goriely, S, Seidel, L, Michiels, J, Willems, B, Goossens, ME, Beguin, Y, Marchant, A & Baron, F 2022, 'Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients', Cancer Cell, vol. 40, no. 4, pp. 335-337. https://doi.org/10.1016/j.ccell.2022.02.005

TY - JOUR

T1 - Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

AU - Canti, Lorenzo

AU - Ariën, Kevin K

AU - Desombere, Isabelle

AU - Humblet-Baron, Stéphanie

AU - Pannus, Pieter

AU - Heyndrickx, Leo

AU - Henry, Aurélie

AU - Servais, Sophie

AU - Willems, Evelyne

AU - Ehx, Grégory

AU - Goriely, Stanislas

AU - Seidel, Laurence

AU - Michiels, Johan

AU - Willems, Betty

AU - Goossens, Maria E

AU - Beguin, Yves

AU - Marchant, Arnaud

AU - Baron, Frédéric

N1 - FTX; (Elsevier User License)

PY - 2022

Y1 - 2022

KW - Antibody Formation

KW - BNT162 Vaccine

KW - COVID-19/prevention & control

KW - Humans

KW - SARS-CoV-2

KW - Vaccination

U2 - 10.1016/j.ccell.2022.02.005

DO - 10.1016/j.ccell.2022.02.005

M3 - A1: Peer-reviewed journal articles

C2 - 35172125

SN - 1535-6108

VL - 40

SP - 335

EP - 337

JO - Cancer Cell

JF - Cancer Cell

IS - 4

ER -

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

Keywords

Access to Document

Projects

ImmCoV: Are SARS-CoV-2 specific antibodies a correlate for protection?)

Cite this